The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis. II. High initial dose
Frick, J.; Bartsch, G.; Weiske, W.H.
Contraception 15(6): 669-677
1977
ISSN/ISBN: 0010-7824 PMID: 891193 DOI: 10.1016/s0010-7824(77)80004-8Document Number: 439736
Document emailed within 0-6 h
Related Documents
Frick, J.; Bartsch, G.; Weiske, W.H. 1977: The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis. I. Uniform dosage levels Contraception 15(6): 649-668Melo, J.F.; Coutinho, E.M. 1977: Inhibition of spermatogenesis in men with monthly injections of medroxyprogesterone acetate and testosterone enanthate Contraception 15(6): 627-634
Wils, J.A. 1988: Myeloprotective effect of high dose medroxyprogesterone acetate (MPA) Chemioterapia: International Journal of the Mediterranean Society of ChemoTherapy 7(1): 60-62
Zia, Y.; Tang, J.H.; Chinula, L.; Tegha, G.; Stanczyk, F.Z.; Kourtis, A.P. 2019: Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi Contraception 100(5): 402-405
Gai, L.; Zhang, J.; Zhang, H.; Gai, P.; Liu, Y. 2009: Effect of Depot Medroxyprogesterone Acetate (DMPA) on Bone Mineral Density in Women of Reproductive Age Journal of Reproduction and Contraception 20(1): 51-56
Chandra, N.; Thurman, A.R.; Anderson, S.; Cunningham, T.D.; Yousefieh, N.; Mauck, C.; Doncel, G.F. 2013: Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues Aids Research and Human Retroviruses 29(3): 592-601
Harris, T.G.; Miller, L.; Kulasingam, S.L.; Feng, Q.; Kiviat, N.B.; Schwartz, S.M.; Koutsky, L.A. 2009: Depot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection American Journal of Obstetrics and Gynecology 200(5): 489.E1-8
Sturm, G.; Antal, E.; Schmidt Rhode, P.; Bauer, T.; Schulz K D. 1986: Medroxyprogesterone acetate and immunoreactive medroxyprogesterone acetate metabolites measured by two different selective radioimmunoassay antibodies in medroxyprogesterone acetate treated breast cancer patients Anticancer Research 6(3 Part A): 362
Brat, T.; Decoster, J.M.; Molitor-Peffer, M.P. 1979: Six-monthly administration of medroxyprogesterone acetate (MPA) Journal de Gynecologie Obstetrique et Biologie de la Reproduction 8(7): 659-662
Day, S.; Graham, S.M.; Masese, L.N.; Richardson, B.A.; Kiarie, J.N.; Jaoko, W.; Mandaliya, K.; Chohan, V.; Overbaugh, J.; McClelland, R.S. 2014: A prospective cohort study of the effect of depot medroxyprogesterone acetate on detection of plasma and cervical HIV-1 in women initiating and continuing antiretroviral therapy Journal of Acquired Immune Deficiency Syndromes 66(4): 452-456
Modesto, W.; Bahamondes, M.V.; Silva dos Santos, P.; Fernandes, A.; Dal'Ava, N.; Bahamondes, L. 2014: Exploratory study of the effect of lifestyle counselling on bone mineral density and body composition in users of the contraceptive depot-medroxyprogesterone acetate European Journal of Contraception and Reproductive Health Care: the Official Journal of the European Society of Contraception 19(4): 244-249
Pannuti, F.; Camaggi, C.M.; Strocchi, E.; Giovannini, M.; Di Marco, A.R.; Costanti, B. 1982: Medroxyprogesterone acetate (MAP) relative bioavailability after single high-dose administration in cancer patients Cancer Treatment Reports 66(12): 2043-2049
Linthorst, G.; Wibaut, E.P.; de Jongh, R.E. 1972: Experiences with a 3-monthly injections of medroxyprogesterone acetate (MPA) as a contraceptive agent Nederlands Tijdschrift Voor Geneeskunde 116(38): 1694-1698
Sasagawa, I.; Satomi, S.; Katayama, T. 1989: Remarkable pain relief in the treatment with high-dose medroxyprogesterone acetate in advanced prostatic carcinoma Gan no Rinsho. Japan Journal of Cancer Clinics 35(6): 767-771
Sica, G.; Iacopino, F.; Marini, L.; Robustelli della Cuna, G. 1992: Antiproliferative effect of leuprorelin acetate, alone or combined with tamoxifen or medroxyprogesterone acetate, on human breast cancer cell lines Clinical Therapeutics 14 Suppl A: 87-96
Kjaer, M.; Frederiksen, P.L. 1986: High-dose medroxyprogesterone acetate in patients with renal adenocarcinoma and measurable lung metastases: a phase Ii study Cancer Treatment Reports 70(3): 431-432
Bakry, S.; Merhi, Z.O.; Scalise, T.J.; Mahmoud, M.S.; Fadiel, A.; Naftolin, F. 2008: Depot-medroxyprogesterone acetate: an update Archives of Gynecology and Obstetrics 278(1): 1-12
Cromwell, P.; Anyan, W. 1998: Depot medroxyprogesterone acetate galactorrhea Journal of Adolescent Health: Official Publication of the Society for Adolescent Medicine 23(2): 61
Bonhomme, M.G.; Potts, D.M.; Fortney, J.A.; Allen, M.Y. 1991: Safety of depot medroxyprogesterone acetate Lancet 338(8772): 942
Gai, L.; Zhang, J.; Zhang, H.; Gai, P.; Zhou, L.; Liu, Y. 2011: The effect of depot medroxyprogesterone acetate (DMPA) on bone mineral density (BMD) and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age Contraception 83(3): 218-222